Stocks Health care LXEO
NASDAQ · Health careLexeo Therapeutics, Inc. (LXEO)
It posted a net loss of $87.3M. In fiscal 2025 capital spending exceeded operating cash flow by $99M. At June 30, 2026 it held $92.8M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 12, 2026.
Key facts about Lexeo Therapeutics, Inc.
- Net worth
- Lexeo Therapeutics, Inc. has a market value (market cap) of $257.6M at the latest share price, and shareholders' equity of $235.1M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2023 revenue was $654K, with a net loss of $59.3M.
- Cash flow
- In fiscal 2025 operations used $98.6M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 12, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Lexeo Therapeutics, Inc.'s next report was expected around October 16, 2026 and is not on file with the SEC yet.
What Lexeo Therapeutics, Inc. does
Lexeo Therapeutics, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker LXEO.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$100M | -$1.86 | -$99M |
| 2024 | n/a | -$98.3M | -$3.09 | -$81.6M |
| 2023 | n/a | -$66.4M | -$12.40 | -$59.6M |
| 2023 | $654K | -$59.3M | -$36.36 | -$55.2M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Lexeo Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 29, 2026
- October 13, 2026Passive stake (5% or more) SCHEDULE 13G
- September 29, 2026Acquisition or sale completed8-KLexeo Therapeutics completed the acquisition of Mantle Therapeutics.
- September 22, 2026Material agreement8-KLexeo Therapeutics agreed to acquire Mantle Therapeutics to expand its Friedreich ataxia pipeline.
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 13, 2026Passive stake changed SCHEDULE 13G/A
- August 12, 2026
- August 12, 2026
Insider trades
What the people running Lexeo Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $43.2K worth of shares in the last 90 days and bought none on the open market.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 14, 2026 | Townsend Richard NolanChief Executive Officer, Director | Received as pay | 2,306 | $6.1K |
| September 14, 2026 | Otero Jose ManuelChief Operating Officer | Received as pay | 2,110 | $5.6K |
| September 14, 2026 | Bhalla Narinder PalChief Medical Officer | Received as pay | 2,714 | $9.7K |
| August 18, 2026 | Townsend Richard NolanChief Executive Officer, Director | Sold | 3,345 | $16.6K |
| August 18, 2026 | Otero Jose ManuelChief Operating Officer | Sold | 1,304 | $6.5K |
| August 18, 2026 | Tamayo Louis EdwardChief Financial Officer | Sold | 4,117 | $20.2K |
| July 1, 2026 | Townsend Richard NolanChief Executive Officer, Director | Sold | 25,947 | $116.2K |
| July 1, 2026 | Otero Jose ManuelChief Operating Officer | Sold | 4,666 | $20.9K |
Who owns LXEO
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Balyasny Asset Management L.P.13G, passive with 4 related filers | 9.99% | August 14, 2026 |
| Janus Henderson Group PLC13G, passive | 9.99% | December 8, 2025 |
| Affinity Asset Advisors, LLC13G, passive with 1 related filers | 8.4% | August 13, 2026 |
| Suvretta Capital Management, LLC13G, passive with 2 related filers | 7.7% | April 13, 2026 |
| Vestal Point Capital, LP13G, passive with 1 related filers | 7.5% | November 14, 2025 |
| Kenneth Griffin13G, passive with 6 related filers | 7.4% | February 17, 2026 |
| RA Capital Management, L.P.13G, passive with 3 related filers | 6.9% | October 27, 2025 |
| Paradigm BioCapital Advisors LP13G, passive with 3 related filers | 5.3% | August 14, 2026 |
| Frazier Life Sciences Public Fund, L.P.13G, passive with 13 related filers | 5.1% | February 13, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 142 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Montanova Capital, LLC | 6,384,200 | +5,134,200 |
| Affinity Asset Advisors, LLC | 5,807,611 | +757,400 |
| BlackRock, Inc. | 5,739,455 | +628,584 |
| RA Capital Management, L.P. | 5,000,000 | 0 |
| Frazier Life Sciences Management, L.P. | 4,824,725 | +400,000 |
| State Street Corp | 4,354,757 | +786,515 |
| Vestal Point Capital, LP | 4,320,000 | -155,000 |
| Paradigm Biocapital Advisors LP | 4,175,382 | -2,008,752 |
| Jupiter Topco LLC | 3,954,691 | new |
| Orbimed Advisors LLC | 3,947,850 | +345,400 |
| Citadel Advisors LLC | 3,898,570 | +63,571 |
| Vanguard Capital Management LLC | 3,125,893 | +118,800 |
| Millennium Management LLC | 2,833,622 | +1,220,842 |
| Nantahala Capital Management, LLC | 2,600,000 | +1,400,000 |
| Woodline Partners LP | 2,500,532 | -250,000 |
| Balyasny Asset Management L.P. | 2,412,742 | +823,157 |
| Goldman Sachs Group Inc | 2,149,612 | +199,727 |
| 683 Capital Management, LLC | 1,875,000 | +675,000 |
| Geode Capital Management, LLC | 1,747,959 | +234,182 |
| ADAR1 Capital Management, LLC | 1,565,950 | +98,600 |
Insiders
7 insiders reported holding 899,384 shares in total, about $2.8M at the last price.
| Holder | Shares |
|---|---|
| Townsend Richard NolanChief Executive Officer, Director | 376,778 |
| Otero Jose ManuelChief Operating Officer | 138,288 |
| Tamayo Louis EdwardChief Financial Officer | 92,907 |
| Bhalla Narinder PalChief Medical Officer | 84,908 |
| Adler EricChief Medical Officer | 72,646 |
| Robertson JennyChief Legal Officer | 68,381 |
| See Tai SandiChief Development Officer | 65,476 |
Questions about LXEO
What does Lexeo Therapeutics, Inc. do?
Lexeo Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as LXEO. Its shares trade on NASDAQ under the ticker LXEO.
What is Lexeo Therapeutics, Inc.'s net worth?
Lexeo Therapeutics, Inc. has a market value (market cap) of $257.6M at the latest share price, and shareholders' equity of $235.1M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Lexeo Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $87.3M.
When did Lexeo Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 12, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the shelf registration to sell securities from October 29, 2026.
When is Lexeo Therapeutics, Inc.'s next earnings report?
Lexeo Therapeutics, Inc.'s next report was expected around October 16, 2026 and is not on file with the SEC yet.
Similar companies
Compare LXEO with
Follow LXEO
Get an email when Lexeo Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Lexeo Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.